{"id":"at7519m","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting JAK2, AT7519M reduces the activity of the JAK2 protein, which is involved in the signaling of various cytokines and growth factors. This can lead to the inhibition of tumor growth and proliferation.","oneSentence":"AT7519M is a potent inhibitor of the JAK2 protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:36.504Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myeloproliferative neoplasms"}]},"trialDetails":[{"nctId":"NCT02503709","phase":"PHASE1","title":"Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-09-30","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm","enrollment":29},{"nctId":"NCT01183949","phase":"PHASE1, PHASE2","title":"Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2010-11","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT01627054","phase":"PHASE2","title":"A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2012-08-27","conditions":"Chronic Lymphocytic Leukemia","enrollment":7},{"nctId":"NCT00390117","phase":"PHASE1","title":"AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-01-05","conditions":"Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":34},{"nctId":"NCT01652144","phase":"PHASE2","title":"A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2012-09-14","conditions":"Mantle Cell Lymphoma","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AT7519M","genericName":"AT7519M","companyName":"Astex Pharmaceuticals, Inc.","companyId":"astex-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AT7519M is a potent inhibitor of the JAK2 protein. Used for Myeloproliferative neoplasms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}